Therapeutic targets in idiopathic pulmonary fibrosis

Area of Science:

• Pulmonology
• Pharmacology
• Interstitial Lung Diseases

Background:

• Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with limited treatment options.
• Despite recent advances, the prognosis for IPF patients remains poor, necessitating further therapeutic development.
• Understanding IPF pathogenesis has led to approved therapies, but the search for more effective treatments is ongoing.

Purpose of the Study:

• To review the mechanisms of action for approved IPF therapies, nintedanib and pirfenidone.
• To discuss investigational compounds in Phase II trials for IPF treatment.
• To explore the potential of combination therapy in managing IPF.

Main Methods:

• Literature review of approved IPF therapies.
• Review of ongoing Phase II clinical trials for IPF investigational drugs.
• Discussion of therapeutic pathways and combination strategies for IPF.

Main Results:

• Nintedanib and pirfenidone are approved therapies that slow IPF progression.
• Several investigational compounds targeting IPF pathways are in Phase II trials.
• Combination therapy may offer enhanced efficacy for IPF treatment.

Conclusions:

• Approved therapies offer benefits but do not halt IPF progression.
• Investigational drugs show promise in targeting specific IPF pathogenic pathways.
• Combination therapies represent a potential future strategy for improved IPF management.